Catheter Precision, Inc.
2.4400-0.12 (-4.76%)
Oct 29, 4:00:00 PM EDT · NYSE American · VTAK · USD
Key Stats
Market Cap
3.63MP/E (TTM)
0.07Basic EPS (TTM)
33.63Dividend Yield
0%Recent Filings
8-K
Stockholders approve share increase
Catheter Precision stockholders approved an amendment on October 10, 2025, boosting authorized common shares from 60 million to 500 million, with 497,162 votes for and 133,882 against at the special meeting. They also ratified WithumSmith+Brown, PC as auditors for fiscal 2026, garnering 610,134 yes votes. This share increase equips the company for potential equity raises. Yet opposition signals investor caution.
8-K
UK Approval for LockeT
Catheter Precision secured approval for its LockeT suture retention device in the United Kingdom on August 18, 2025, following CE Mark clearance in May 2025. The company partnered with distributor HC21 to drive commercialization, aiming to boost patient comfort, speed recovery, and enable earlier discharges after cardiac procedures. This supports NHS efforts to cut waiting lists. Yet competition looms large.
8-K
1-for-19 reverse split executed
Catheter Precision executed a 1-for-19 reverse stock split, effective August 15, 2025, slashing outstanding shares from 23,327,516 to 1,227,764 while preserving ownership percentages. No fractional shares issued; holders get pro rata cash from sales instead. Adjustments hit options, warrants, and registration statements proportionally. This sharp cut aims to meet NYSE American standards, yet risks diluting liquidity further.
10-Q
Q2 FY2025 results
Catheter Precision posted Q2 revenue of $212K, up 128% y/y from $93K, driven by LockeT sales ramping to $102K (derived) while VIVO dipped slightly; gross margin held steady at 93% despite scale. Operating loss widened to $4.7M from $2.7M y/y, fueled by $1.8M IPR&D hit from Cardionomix CPNS asset buyout in May for $1.9M (stock/note mix, no goodwill), yet net loss narrowed to $5.1M or $(0.38) per share on 13.3M diluted shares—better than $(5.57) on 0.8M shares last year, thanks to tax benefits. Cash burned $4.6M YTD to $0.8M, with $2.6M raised via PIPE and ATM; related-party debt stands at $1.5M due Jan 2026 (12% rate). New KardioNav sub formed June for VIVO IP integration, eyeing pre-ablation mapping. Competition from bigger EP players could squeeze margins further.
8-K
Revenue surges 128% YoY
Catheter Precision reported Q2 2025 revenue of $212 thousand, up 128% from Q2 2024 and 48% sequentially, while first-half revenue hit $355 thousand, a 103% jump year-over-year. The company secured CE Mark for its LockeT device, paving the way for European sales in Q3, and unveiled strong clinical data at the Heart Rhythm Society symposium showing VIVO's 94% accuracy in arrhythmia mapping. It also completed the Cardionomic asset acquisition via 82%-owned Cardionomix and formed majority-owned Kardionav for ventricular tachyarrhythmia tech. Cash stood at $838 thousand amid a $5.4 million quarterly net loss, mostly non-cash.
IPO
Employees
Sector
Industry
CLPT
ClearPoint Neuro Inc.
24.11-2.87
CV
CapsoVision, Inc.
4.67-0.01
CVRX
CVRx, Inc.
10.81+0.09
EBRCZ
EBR SYSTEMS INC NPV CDI 1:1
0.95+0.00
EW
Edwards Lifesciences Corporatio
82.69+0.50
HSCS
HeartSciences Inc.
2.97-0.19
MDNC
MEDINOTEC INC
5.00+0.00
MDT
Medtronic plc.
91.73-1.50
RBOT
Vicarious Surgical Inc.
5.45-0.30
VYCO
Vycor Medical, Inc.
0.15+0.00